Life Sciences

We create and invest in leading companies in therapeutics and medtech. If we can’t find a company solving an important problem, we create one ourselves — just like we did with Innovent, Denali, Beam, and Ultragenyx to name a few.

Life Sciences Portfolio

Spotlights Portfolio List People Impact

Portfolio List

Explores Glia's role in brain disease, acquired by Neumora.
Acquired by Neumora
Develops innovative therapies for unmet needs in dermatology and immunodermatology.
NASDAQ:ACRS
Uses Smart Antibody Technology to accelerate development and reduce costs in antibody discovery.
NASDAQ: ADAG
Develops protein conjugate therapies, combining biologics and small molecule payloads to treat cancer.
Developing a protein nanoparticle (PNP) delivery platform.
Develops transformative gene therapies for devastating diseases using rationally designed AAV vectors.
Develops targeted radioligand therapies (RLTs) to improve cancer treatment globally.
Develops precision medicines targeting protein synthesis for breakthrough cancer therapies.
Develops novel therapies by inhibiting the complement system at the C3 level.
NASDAQ: APLS
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Developing neurodegenerative disease treatments using proprietary RNA interference platform.
Develops improved therapies for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases.
Develops CAR-T cell therapies using switchable and scalable platforms for cancers.
Pioneering gene therapy company focused on transformative medicines for neurodegenerative disorders.
Developing innovative neuromodulation technology to treat large disease populations.
Pioneering CRISPR base editing for precision genetic medicines to treat disease.
NASDAQ: BEAM
Develops biologics combining targeted therapy with tumor modulators to enhance immune activity.
NASDAQ:BCAX
Focuses on developing therapies for diseases of the eye.
Acquired by Shire
Developing base editing technology for a range of applications.
Precision therapy company striving to improve human health.
Acquired by Sanofi / NASDAQ: BPMC
Rapidly growing pharmaceutical company focusing on emerging markets and expanding into regulated markets.
Developed lixivaptan for hyponatremia treatment.
Acquired by Cornerstone Therapeutics
Pioneering CRISPR genome editing for new medical therapies.
NASDAQ: CRBU
Immune-activating cancer therapy company acquired by Regeneron in 2022, developed vidutolimod.
Acquired by Regeneron / NASDAQ: CMPI
Develops and commercializes consumer healthcare and over-the-counter products.
Develops targeted therapies for oncology.
NASDAQ:COGT
Develops and commercializes high-quality biosimilar therapeutics worldwide using advanced analytics.
Developing the first therapy targeting a root cause of preterm preeclampsia to reduce risks for mothers and babies, including premature birth.
Develops antibodies targeting tumor-immune synapse for comprehensive cancer treatment.
NASDAQ: CMPX
Leader in discovery and development of novel drugs in stem cell related diseases.
Seed-stage venture firm and accelerator for therapeutics startups, providing expertise and capital.
Developing therapies for neurodegenerative diseases through rigorous research.
NASDAQ: DNLI
AAV gene therapy developer for rare diseases.
Acquired by Ultragenyx Pharmaceuticals
Developing curative medicines through precision in vivo cellular engineering.
Specializing in biosimilars and novel biologics for global healthcare markets.
Focused on affordable, high-quality medicines for patients worldwide.
Developing small molecule therapeutics for protein misfolding and aggregation diseases.
Acquired by Pfizer
Improving diagnostic testing and accelerate drug discovery in diverse underserved populations.
Leading animal vaccine manufacturer in China.
603718.SS
Developing innovative drugs for diabetes and related metabolic disorders.
2552.KHK
Developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.
Acquired by UCB
Leading the change in cell & gene therapies & personalized immunotherapy.
Dedicated to developing novel treatments for fibrotic diseases.
Developing and commercializing high-quality biologic medicines.
1801.HK
Harnessing deep learning to accelerate pharmaceutical development.
Developing novel protein-based therapeutics for companion animals.
Acquired by Dechra
Developing and commercializing innovative medicines focused on gastrointestinal diseases.
NASDAQ: IRWD
Developing novel treatments for unmet medical needs.
Targets epigenetic pathways to develop innovative cancer therapies.
Developing innovative therapies for autoimmune and inflammatory diseases.
NASDAQ: LSB
Research-driven pharmaceutical manufacturing organization.
NSE: LAURUSLABS
Developing nasal spray products to prevent respiratory viruses.
Developing innovative vaccines for the prevention of gastrointestinal diseases.
Acquired by Takeda
Developing antibody-drug conjugates for cancer treatment.
NASDAQ: MRSN
Bringing cell-based therapies to heart failure patients.
Developing next-generation medicines for obesity and metabolic diseases.
NASDAQ: MTSR
Develops targeted therapies for rare genetic diseases and mitochondrial disorders.
Acquired by Zogenix
Developing precision medicines for brain diseases.
NASDAQ: NMRA
Creates and promotes differentiated products in the pediatric market.
Acquired by Pfizer
Develops targeted therapies for fibrotic diseases and other dermatological conditions.
Developing novel therapeutics for neurogenic cough and inflammation.
Develops innovative therapies to address unmet medical needs in various diseases.
Acquired by SciClone
Accelerating the advancement of globally competitive oncology assets for patients.
Offers clean-label wellness supplements for health-conscious consumers through plant-based nutrition.
Developing and introducing effective and clinically proven children's medicines for China.
Developing and supplying plasma protein therapies for the treatment of rare and chronic diseases.
Engineering advanced therapies for genetic and oncological diseases through genome editing.
NASDAQ: DTIL
Pioneering gene-editing solutions using precision genome engineering technologies.
NASDAQ: PRME
Developing therapies for neuropsychiatric and neurodevelopmental disorders.
Developing therapies targeting protein misfolding diseases.
Merged with Yumanity Therapeutics in 2020
Developing transformative therapies for devastating rare diseases.
NASDAQ: RLYB
Developing and commercializing therapies for rare diseases in Asia.
Advancing AAV-based treatments for rare genetic diseases through gene therapy.
NASDAQ: RGNX
Developing gene therapies for retinal diseases causing blindness.
Developing RNA-based therapeutics for immune modulation and viral defense.
Discovering and developing novel first-in-class small molecule drugs with the potential to address multiple psychiatric indications.
Developing cell and gene therapies for complex diseases.
NASDAQ: SANA
Developing cell therapies for treating type 1 diabetes.
Acquired by Vertex
Pioneering novel immunotherapies for cancer treatment.
Facilitating data-driven life science research and empowering drug R&D processes.
Developing treatments for age-related degenerative diseases.
Developing innovative treatments for genetic diseases through gene therapy.
Developing oral therapies for chronic metabolic and cardiovascular diseases.
NASDAQ: GPCR
Developing next-generation antibody therapies focused on the tumor microenvironment.
NASDAQ:SURF
Developing innovative treatments for women’s health conditions.
Transforming global drug discovery with advanced AI and physics-based technologies.
Develops small molecule therapeutics designed to effectively treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
NASDAQ: TPST
Improving the lives of patients and caregivers impacted by neurological, cardiometabolic, and ophthalmic diseases.
Developing antibiotics for multi-drug-resistant infections.
NASDAQ: TTPH
Developing treatments for pediatric infectious diseases.
Acquired by Sanofi
Developing inhaled therapies for respiratory and lung infections.
Acquired by Insmed Inc.
Developing cancer therapies that activate T-cell responses through immuno-oncology.
NASDAQ: TSBX
Developing innovative treatments for rare and ultra-rare diseases.
NASDAQ: RARE
Developing treatments for cardiovascular diseases though gene-editing.
NASDAQ: VERV
Developing treatments for dermatological conditions like rosacea.
Acquired by Allergan
Developing treatments for immuno-inflammatory conditions.
NASDAQ: VYNE
Engineering tumor-activated therapies for targeted cancer treatment.
NASDAQ: XLO
The companies identified do not represent all the companies purchased, sold, or recommended for portfolios advised by F-Prime. A full list of investments made by funds managed by F-Prime is available below.

People

Alex Pasteur, Ph.D.
Alexander Munoz, M.D.
Amber Cai, Ph.D.
Anastasiya Sybirna, Ph.D.
Bobby Gaspar, M.D., Ph.D.
Brian Yordy, Ph.D.
Carlos Bustamante, Ph.D.
Carolyn Haley, M.S., CPA
Catherine Stehman-Breen
Chong Xu, Ph.D.
Clare Bernard
Connie Li
Garth Rapeport
Harlan Krumholz, M.D.
Jessica Alston, Ph.D.
John Shiver, Ph.D.
Ketan Patel, M.D.
Kevin Chu
Martin Taylor, Ph.D.
Mike Feng
Muzammil Mansuri, Ph.D.
Namandjé N. Bumpus, Ph.D.
Natasha Rodgers, MB BChir
Nicholas Haining, BM, BCh
Nihal Sinha, MB BChir
Nikhil Ananth
Raj Basak, Ph.D.
Robert Weisskoff, Ph.D.
Stacie Weninger, Ph.D.
Stephen Knight, M.D.
Thomas Beck, M.D.

Impact